Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Results from Phase 3 trials for non-infectious uveitis treatment ➤ FDA allows new gene therapy for Leber congenital amaurosis to begin clinical testing ➤ FDA approves OTC drop for redness ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ Presbyopia-correcting eye drop receives FDA approval ➤ Four-year, first-in-human results for IOL-based drug delivery system ➤ FDA approves new treatment for thyroid eye disease ➤ New registry establishes baseline for interventional glaucoma procedures in the U.S. ➤ Phase 3 study for DME does not meet primary endpoint, triggering strategic decisions ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ Phase 4 results for iDose TR ➤ Phase 3 extension study showcases positive results with epithelium-on crosslinking ➤ 6-month results from bio-reinforced canaloplasty procedure for glaucoma ➤ Dosing update in Phase 1 study evaluating mRNA treatment of optic atrophy ➤ Enrollment complete in Phase 2a study for geographic atrophy ➤ IND amendment submitted to FDA to expand indication for product candidate ➤ Complimentary access to video journal ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ Nobel Prize awarded to scientists in optogenetics ➤ Positive safety, efficacy data for X-linked retinoschisis therapy ➤ Study: 3-year, real-world outcomes of switch to faricimab for nAMD ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ FDA approves ‘world’s first’ spiral IOL platform ➤ Company to submit formal appeal after FDA’s denial of dry eye disease NDA ➤ FDA to hold Advisory Committee meeting for low-dose atropine treatment for myopia ➤ Positive results in Phase 3 trial for AMD treatment ➤ Phase 3 trial investigating DME treatment begins ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ Enrollment complete in pivotal trial for first-in-class regenerative cell therapy ➤ First patients dosed in Phase 3 trial for TED treatment ➤ 6-month results with virtual aperture IOL ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ AMA classifies myopia as a disease ➤ Report marks shift in refractive surgery trends ➤ Patient dosing begins in Phase 2 trial for oral DME therapy ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ IDE approval for initiation of feasibility study for glaucoma uveal spacer ➤ Launch of premium ophthalmic microscope ➤ Acceptance of BLA for treatment of retinitis pigmentosa with severe vision loss ➤ Launch of new feature for virtual reality patient education platform ➤ Launch of new pretest for VR-powered diagnostic headset ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ FDA accepts NDA for investigational IOP-lowering eye drop for patients with open-angle glaucoma or ocular hypertension ➤ First patient dosed in Phase 3 registrational trial for GA secondary to dry AMD ➤ New survey highlights awareness gap around dry eye association with perimenopause/menopause ➤ ASCRS news and events ➤ EyeWorld article of the week
➤ First and only MGD treatment indicated to improve meibomian gland function in patients with evaporative dry eye ➤ First patient treated in registrational trial for optic neuritis ➤ Data in patient-reported discomfort following intravitreal injections ➤ Two first-in-class treatments advancing based on trial results ➤ Company news ➤ ASCRS news and events ➤ EyeWorld article of the week
Get the latest ophthalmology news delivered to your inbox every Friday.